Agilent Technologies, Inc. (NYSE:A) Shares Sold by Harvey Investment Co. LLC

Harvey Investment Co. LLC lowered its stake in Agilent Technologies, Inc. (NYSE:AFree Report) by 1.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 217,132 shares of the medical research company’s stock after selling 2,150 shares during the period. Agilent Technologies makes up approximately 3.4% of Harvey Investment Co. LLC’s portfolio, making the stock its 9th biggest holding. Harvey Investment Co. LLC owned about 0.08% of Agilent Technologies worth $29,170,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. CKW Financial Group boosted its holdings in Agilent Technologies by 114.9% in the 4th quarter. CKW Financial Group now owns 187 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 100 shares in the last quarter. Global X Japan Co. Ltd. raised its stake in shares of Agilent Technologies by 161.1% during the 4th quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock worth $25,000 after buying an additional 116 shares in the last quarter. Livelsberger Financial Advisory acquired a new stake in shares of Agilent Technologies in the 3rd quarter valued at approximately $28,000. Ashton Thomas Securities LLC purchased a new stake in shares of Agilent Technologies in the third quarter valued at approximately $31,000. Finally, Fortitude Family Office LLC grew its holdings in Agilent Technologies by 68.3% during the third quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock worth $35,000 after acquiring an additional 95 shares during the period.

Agilent Technologies Stock Down 0.2 %

A opened at $147.66 on Friday. The firm has a market cap of $42.17 billion, a P/E ratio of 33.41, a PEG ratio of 4.10 and a beta of 1.07. The business’s fifty day simple moving average is $141.44 and its 200 day simple moving average is $139.19. Agilent Technologies, Inc. has a 52 week low of $124.16 and a 52 week high of $155.35. The company has a quick ratio of 1.58, a current ratio of 2.09 and a debt-to-equity ratio of 0.57.

Agilent Technologies (NYSE:AGet Free Report) last released its quarterly earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.41 by $0.05. The company had revenue of $1.70 billion for the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. The firm’s revenue for the quarter was up .8% compared to the same quarter last year. During the same period last year, the company earned $1.38 EPS. As a group, equities research analysts anticipate that Agilent Technologies, Inc. will post 5.56 EPS for the current fiscal year.

Agilent Technologies Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, January 22nd. Shareholders of record on Tuesday, December 31st were issued a $0.248 dividend. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.24. The ex-dividend date was Tuesday, December 31st. This represents a $0.99 annualized dividend and a yield of 0.67%. Agilent Technologies’s payout ratio is 22.40%.

Insider Activity

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total transaction of $286,650.00. Following the completion of the transaction, the chief executive officer now directly owns 39,652 shares of the company’s stock, valued at $5,947,800. This trade represents a 4.60 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Analysts Set New Price Targets

A has been the subject of a number of recent analyst reports. Bank of America reduced their target price on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Wells Fargo & Company reduced their price objective on shares of Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a research note on Monday, December 9th. Barclays lowered their target price on shares of Agilent Technologies from $145.00 to $135.00 and set an “underweight” rating on the stock in a research report on Wednesday, November 27th. StockNews.com upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 24th. Finally, Sanford C. Bernstein decreased their price target on Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a research note on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $143.62.

Read Our Latest Analysis on A

Agilent Technologies Profile

(Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Recommended Stories

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:AFree Report).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.